Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Explore linked clinical trials.115 results ยท Page 1 of 5
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-10-08 | NCT06059690 | |
| Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Urogenital Diseases, cervix disorder, dysplasia of cervix, female reproductive system disorder, neoplasm, precancerous condition, uterine disorder | Active, not recruiting | Phase 2 | 2026-10-06 | NCT04712851 | |
| Ivonescimab for the Treatment of Thymic Cancer | thymic carcinoma | Recruiting | Phase 2 | 2026-10-05 | NCT06980077 | |
| An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer. | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate carcinoma, prostate disorder | Recruiting | Phase 2 | 2026-09-29 | NCT07185165 | |
| ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, gliosarcoma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 | 2026-09-18 | NCT07089641 | |
| Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma | Oligometastatic Prostate Adenocarcinoma; Recurrent Prostate Adenocarcinoma | Recruiting | Phase 2 | 2026-09-17 | NCT07150715 | |
| 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, neoplasm, sarcoma | Active, not recruiting | Early phase 1 | 2026-09-17 | NCT04457258 | |
| A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Not applicable | 2026-09-02 | NCT06568016 | |
| Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms | neoplasm | Active, not recruiting | Phase 2 | 2026-09-01 | NCT06788938 | |
| Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Tumors, ONE SHOT Trial | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Not yet recruiting | Not applicable | 2026-08-24 | NCT07671768 | |
| Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-08-21 | NCT06432036 | |
| Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pancreatic Carcinoma, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast carcinoma, breast disorder, breast neoplasm, carcinoma, carcinoma of esophagus, colon carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric carcinoma, gastric neoplasm, gonadal disorder, head and neck carcinoma, intestinal disorder, kidney cancer, kidney disorder, lung carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder, pancreas disorder, pancreatic neoplasm, renal carcinoma, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, stomach disorder, urinary system disorder, uterine corpus cancer | Active, not recruiting | Early phase 1 | 2026-08-21 | NCT04147494 | |
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, cholangiocarcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 | 2026-08-20 | NCT07619313 | |
| Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial | invasive breast carcinoma | Recruiting | Phase 2 | 2026-08-20 | NCT07191717 | |
| Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Not stated | 2026-08-20 | NCT07077239 | |
| Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Not applicable | 2026-08-20 | NCT06995053 | |
| Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Not applicable | 2026-08-20 | NCT06538337 | |
| Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer | colorectal adenocarcinoma | Recruiting | Phase 1 | 2026-08-20 | NCT06225011 | |
| High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate adenocarcinoma, prostate cancer, prostate disorder | Recruiting | Not applicable | 2026-08-20 | NCT04945642 | |
| Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate carcinoma, prostate disorder | Active, not recruiting | Phase 1 | 2026-08-20 | NCT04457232 | |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 1 | 2026-08-20 | NCT04007029 | |
| Pembrolizumab in Treating Participants With Leukoplakia | Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, leukoplakia, neoplasm, precancerous condition | Recruiting | Phase 2 | 2026-08-20 | NCT03603223 | |
| External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer | cervical adenocarcinoma, cervical adenosquamous carcinoma, cervical squamous cell carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-08-12 | NCT06543576 | |
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, connective tissue disorder, connective tissue neoplasm, epithelial neoplasm, hereditary leiomyomatosis and renal cell cancer, kidney cancer, kidney disorder, leiomyoma cutis, myofibroma, neoplasm, renal cell carcinoma, urinary system disorder, uterine corpus leiomyoma | Not yet recruiting | Phase 1 | 2026-08-06 | NCT07716735 | |
| Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors | Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Early Stage Breast Carcinoma | Recruiting | Phase 2 | 2026-07-30 | NCT06113016 |